BOPA encourages its members to share helpful documents that can benefit other members. BOPA respects the intellectual property of original authors and requires anyone who uses other members' work to include an acknowledgment of, or reference to, the source in their version. Please send your document to a member of the committee who will moderate and upload it.
Rapid Infusion for Biosimilar Rituximab’s Formulary Governance PaperTo aid BOPA members in introduction of biosimilar rituximab, please find attached and open access word paper that outlines options for Introduction of Rapid Infusion for Biosimilar Rituximab’s. That has been shared from Northern Cancer Alliance Chemotherapy Group.
( version 1.2 with typo corrections 25.05.17)
WE would encourage BOPA members to take part in an Audit of infusion reactions when they introduce biosimilars, and have included an audit form. Further supporting materials will be uploaded in due course.
Please contact email@example.com or firstname.lastname@example.org for more details, entitling your email Rituximab Reaction Audit.
Note: Permission is granted for the contents of the attached paper to be copied and adopted by other NHS hospitals to aid local decision making but responsibility for accuracy of contents and recommendations in this paper thereafter lies with the user(s) and not with the original author. Members may not publish any part of the paper in any 3rd party source, journal, website etc without prior permission.